Industry context
Capricor Therapeutics Inc [CAPR]
Paskutinį kartą atnaujinta 25 Jun 2026 @ 12:39 (Exchange is open)
Paskutinė: $30.13
2.09%
0.61 (↓)
GaG Algo Score™
v1.0
Trumpas
0.61 (↓)
Vidutinis
1.47 (↓)
Ilgas
1.81 (↓)
PIRKTI
71.43%
grąža 36.52%
PARDUOTI
70.00%
grąža 41.32%
Linija
Pivot duomenys
Pivot statistika
| Rodiklis | Vidurkis | Mediana | Stand. nuokr. |
|---|---|---|---|
| Prieaugis % | 211.98% | 55.63% | 295.71% |
| Nuostolis % | -29.25% | -28.20% | 12.54% |
| Trukmė | 33.5d | 32d | 13.0d |
| Rasta pivot taškų | 7 |
| Prieaugio/nuostolio atkarpos | 6 (3 Prieaugis / 3 Nuostolis) |
| Paskutinis pivot | Top @ $35.34 data 2026-04-21 |
| Pokytis nuo paskutinio pivot | $-5.83 (-16.50%) |
Kito pivot prognozė Paskutinė: $30.13
| Prognozuojamas kitas tipas | Bottom |
| Prognozuojama kaina (vid.) | $25.00 |
| Prognozuojama kaina (mediana) | $25.38 |
| Prognozuojamas kainos intervalas (~68%) | $20.57 - $29.43 |
| Pokytis iki vidutinio tikslo | $-5.13 (-17.01%) |
| Prognozuojama data (vid.) | 2026-05-24 |
| Prognozuojamas datos intervalas (~68%) | 2026-05-11 - 2026-06-06 |
| Pagrindas | Based on 3 historical losses (Avg: -29.25%, Median: -28.20%, StdDev of Abs: 12.54%) and duration (Avg: 33.5 days, StdDev: 13.0 days) |
| Pastaba | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Slight loss for Capricor Therapeutics Inc.
Capricor Therapeutics Inc (CAPR) stock price inched lower on Wednesday after the stock fell $-0.0900 (-0.30%) from the previous session on below-average volume. The stock moved in line with the falling NASDAQ that fell -0.45%. A total of 802 968 stocks were traded yesterday, valued at $23.70M, 8 263 shares more than the previous day (794 705 shares traded). This is below the average volume for the stock at 1.32M shares traded per day.
Capricor Therapeutics Inc signals
There is no conclusive signals given from RSI. The price is above both moving averages, but the short-term average remains below the long-term average; upward momentum is present but not yet fully confirmed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (10%), medium- (10%), and long-term (10%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Capricor Therapeutics Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $30.00. approximately $0.490 (1.66%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $30.4. On a fall back there will be support at $10.3 The dis das resistance s110.3 -
Capricor Therapeutics Inc Evaluation
- Trumpas balas: 0.61
- Vidutinis balas: 1.47
- Ilgas balas: 1.81
Ownership flow
GetAGraph InsiderPower
Transactions
102
Buy power
47.34M
Sell power
7.82M
Reliability
100/100
Buy / sell
6.05
Hist. corr.
-0.59
Latest signal
Sell 2026-04-16
Director 56
Officer 43
Other 2
Major holder 1
2026-05-26
Maurer Michael T Officer
Buy 80 000
2026-05-26
Maurer Michael T Officer
Buy 80 000
2026-05-25
Maurer Michael T Other
Other
2026-05-25
Maurer Michael T Other
Other
2026-05-18
Bergmann Anthony Officer
Buy 3 000
2026-05-18
Bergmann Anthony Officer
Buy 3 000
Relationship map
Correlation snapshot
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.30% <strong>$30.24</strong> paired level.</span>
Event context
Volume and dividends
Long volume corr.
0.09
Short volume corr.
-0.58
Positioning pressure
Short interest pressure
Short interest
24.21%
Of outstanding shares
Short float
27.11%
Of tradable float
Days to cover
14.28
Short interest divided by average volume
Squeeze probability
98.20%
+1.40% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
5
EPS misses
5
Avg. surprise
-29.26%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-11 | - | - | - | - |
| Q2/2025 | 2025-08-06 | - | $-0.430 | - | - |
| Q1/2025 | 2025-05-13 | $-0.530 | $-0.330 | -60.61% | - |
| Q4/2024 | 2025-03-19 | $-0.160 | $-0.310 | 48.39% | 11.13M |
| Q3/2024 | 2024-11-13 | $-0.380 | $-0.340 | -11.76% | 2.26M |
| Q2/2024 | 2024-08-07 | $-0.350 | $-0.320 | -9.37% | 3.97M |
| Q1/2024 | 2024-05-13 | $-0.310 | $-0.110 | -181.82% | 4.91M |
| Q4/2023 | 2024-02-29 | $-0.0200 | $-0.230 | 91.30% | 12.09M |
Analyst view
Analyst targets
Consensus
$50.00
Median
$50.00
Low
$38.00
High
$62.00
News flow
Latest company news
Market coverage
newsfilecorp.com Caprock Announces Closing of Private Placement Jun 19, 2026 newsfilecorp.com Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. Jun 17, 2026 newsfilecorp.com Caprock Announces Proposed Private Placement Jun 12, 2026 newsfilecorp.com Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m Jun 12, 2026Company releases
Company context
Company profile
Birža:
NASDAQ
Sektorius:
Healthcare
Pramonė:
Biotechnology
Currency
USD
Capricor Therapeutics Inc is a clinicalstage biotechnology company which focuses on the development of transformative cell and exosomebased therapeutics for treating Duchenne muscular dystrophy DMD a rare form of muscular dystrophy which results in muscle degeneration and premature death and other diseases with unmet medical needs Its product candidate consists of CAP1002 Engineered Exosomes CAP2003 and ExosomeBased Vaccine The company was founded on June 17 1996 and is headquartered in San Diego CA
Navigation